Pancreatic Cancer Research

ResearcherKumamoto UniversityActive in the last 2 years

Norio Uemura

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5102340560. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2020: 2 papers · 2021: 4 papers · 2022: 1 paper · 2023: 4 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 12

  1. Neoadjuvant Chemotherapy Diminishes Ki-67 Overexpression and Persistent Overexpression Is a Poor Prognostic Factor in Pancreatic Ductal Adenocarcinoma After Pa… Co-author DOI 10.1097/mpa.0000000000002641↗
  2. Hyperglycaemia induces metabolic reprogramming into a glycolytic phenotype and promotes epithelial-mesenchymal transitions via YAP/TAZ-Hedgehog signalling axis… Co-author DOI 10.1038/s41416-022-02106-9↗
  3. Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer. Co-author DOI 10.1172/jci.insight.163022↗
  4. Biological and Clinical Impacts of Glucose Metabolism in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers15020498↗
  5. Statins exert anti-growth effects by suppressing YAP/TAZ expressions via JNK signal activation and eliminate the immune suppression by downregulating PD-L1 exp… Co-author PMID 37293171↗
  6. Thrombospondin-1 overexpression stimulates loss of Smad4 and accelerates malignant behavior via TGF-β signal activation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.tranon.2022.101533↗
  7. Frailty is associated with poor prognosis after resection for pancreatic cancer. Co-author DOI 10.1007/s10147-021-01983-z↗
  8. Proteomic Analysis of Malignant Ascites From Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15071↗
  9. Biological Significance of YAP/TAZ in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3389/fonc.2021.700315↗
  10. Recent advances in artificial intelligence for pancreatic ductal adenocarcinoma. First author DOI 10.3748/wjg.v27.i43.7480↗
  11. Successful Treatment for the Recurrent Liver Metastases of the Pancreatic Cancer by Multimodality Therapy. Co-author DOI 10.1097/mpa.0000000000001622↗
  12. Prognostic Impact of Coagulation Activity in Patients Undergoing Curative Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/invivo.12111↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hiromitsu Hayashi · 12 shared papers, 2020–2026 · strength 1.79
  2. Zhao Liu · 7 shared papers, 2020–2023 · strength 1.04
  3. Katsunori Imai · 7 shared papers, 2020–2023 · strength 0.86
  4. Shigeki Nakagawa · 5 shared papers, 2021–2026 · strength 0.83
  5. Kazuki Matsumura · 6 shared papers, 2020–2023 · strength 0.81
  6. Hiroki Sato · 5 shared papers, 2021–2023 · strength 0.80
  7. Kosuke Mima · 5 shared papers, 2021–2023 · strength 0.69
  8. Fumimasa Kitamura · 5 shared papers, 2020–2023 · strength 0.60
  9. Hideo Baba · 4 shared papers, 2020–2023 · strength 0.52
  10. Tatsunori Miyata · 3 shared papers, 2021–2023 · strength 0.45
  11. Hideo Baba · 3 shared papers, 2021–2023 · strength 0.45
  12. Toru Takematsu · 2 shared papers, 2020–2026 · strength 0.38
  13. Rumi Itoyama · 3 shared papers, 2020–2023 · strength 0.34
  14. Yuki Kitano · 1 shared paper, 2026 · strength 0.27
  15. Hirohisa Okabe · 1 shared paper, 2026 · strength 0.27
  16. Shinsei Yumoto · 1 shared paper, 2026 · strength 0.27
  17. Masaaki Iwatsuki · 1 shared paper, 2026 · strength 0.27
  18. Takatsugu Ishimoto · 2 shared papers, 2021–2023 · strength 0.26
  19. Hideo Baba · 2 shared papers, 2020–2021 · strength 0.25
  20. Takayoshi Kaida · 2 shared papers, 2021–2022 · strength 0.24
  21. Takanobu Yamao · 2 shared papers, 2020 · strength 0.20
  22. Hideo Baba · 1 shared paper, 2023 · strength 0.16
  23. Hidetoshi Nitta · 1 shared paper, 2023 · strength 0.16
  24. Hideo Andreas Baba · 1 shared paper, 2021 · strength 0.15
  25. Luke Bu · 1 shared paper, 2023 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.